Diverse nucleotide offerings 4basebio provides synthetic DNA and mRNA design, manufacture, and supply, plus a proprietary non-viral Hermes delivery system, creating opportunities to sell end-to-end gene therapy and vaccine development solutions.

Customizable delivery platform Hermes nanoparticle vector offers targeted delivery with safety advantages, suggesting upsell potential to clients seeking tissue- or cell-specific delivery for nucleic acid therapeutics beyond conventional LNPs.

Rapid, safe tech edge Unique rapid-turnaround DNA constructs and improved safety profiles can address customers’ timelines and regulatory concerns, enabling faster project kickoffs and competitive differentiation.

Growth-ready funding With substantial funding and a revenue tier indicative of commercial activity, there is appetite for expansion, collaborations, and contract manufacturing opportunities, especially with larger biotech and pharma players.

Strategic fit with partners Comparable peers span sizable biologics and biotech players; target partnerships for plasmid-free workflows, gene editing, and DNA vaccine applications to capture shared market demand and co-development opportunities.